SGLT2抑制剂与GLP-1受体激动剂对2型糖尿病患者血糖指标的影响研究  

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Blood Glu⁃cose Indexes in Patients with Type 2 Diabetes Mellitus

作　　者：韩雪 孙丽[1] HAN Xue;SUN Li(Department of Endocrinology,Siping City Central People's Hospital,Siping 136000,Jilin,China)

机构地区：[1]四平市中心人民医院内分泌科,吉林四平136000

出　　处：《糖尿病新世界》2024年第15期70-73,共4页Diabetes New World

摘　　要：目的探讨2型糖尿病(type 2 diadetes mellitus,T2DM)患者应用钠-葡萄糖共转运蛋白-2(sodium-glucose transporter 2,SGLT2)抑制剂与胰高血糖素样肽1(glucagon-like peptide-1,GLP1)受体激动剂的效果。方法选取2022年2月—2023年3月四平市中心人民医院收治的153例T2DM患者,按治疗方法不同分为对照1组(二甲双胍治疗)、对照2组(二甲双胍+SGLT2抑制剂治疗)与研究组(二甲双胍+SGLT2抑制剂+GLP-1受体激动剂治疗),各51例。比较3组血糖指标、胰岛功能和不良反应发生情况。结果治疗后,3组空腹血糖、餐后2 h血糖、糖化血糖蛋白指标均较治疗前降低,对照2组和研究组均较对照1组低,且研究组低于对照2组,差异有统计学意义(P均<0.05)。治疗后,3组空腹胰岛素水平下降,对照2组和研究组均较对照1组高,且研究组高于对照2组;而胰岛素抵抗指数降低,且对照2组和研究组均较对照1组低,且研究组低于对照2组,差异有统计学意义(P均<0.05)。3组不良反应发生率比较,差异无统计学意义(P>0.05)。结论SGLT2抑制剂与GLP-1受体激动剂在2型糖尿病中的应用效果好,有利于改善患者血糖指标和胰岛素功能,且不会增加不良反应,安全性高。Objective To investigate the effect of sodium-glucose transporter 2(SGLT2)inhibitor and glucagon-like peptide-1(GLP1)receptor agonist in patients with type 2 diabetes mellitus(T2DM).Methods A total of 153 T2DM patients admitted to Siping City Central People's Hospital from February 2022 to March 2023 were selected and di⁃vided into control group 1(metformin treatment),control group 2(metformin+SGLT2 inhibitor treatment)and study group(metformin+SGLT2 inhibitor treatment+GLP-1 receptor agonist treatment)according to different treatment methods,51 cases in each group.Blood glucose indexes,islet function and adverse reactions were compared among the three groups.Results After treatment,fasting plasma glucose,2-hour postprandial plasma glucose and glycated hemoglobin A1c in 3 groups were lower than before treatment,control group 2 and study group were lower than control group 1,and study group was lower than control group 2,the differences were statistically significant(all P<0.05).Af⁃ter treatment,fasting insulin levels in 3 groups were reduced,and control group 2 and study group were higher than control group 1,and study group was higher than control group 2,homeostatic model assessment of insulin resistance was decreased,and both control group 2 and study group were lower than control group 1,and study group was lower than control group 2,the differences were statistically significant(both P<0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion The application of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus was effective,which was conducive to improving blood glu⁃cose index and insulin function of patients,and does not increase adverse reactions,and has higher safety.

关 键 词：钠-葡萄糖共转运蛋白-2 胰高血糖素样肽1受体激动剂 2型糖尿病 血糖指标 

分 类 号：R4[医药卫生—临床医学]